CD74⁺CCL5⁺ effector CD8⁺ T cells drive mucosal inflammation and predict biologics response in inflammatory bowel disease.

ABSTRACT:

Background

Inflammatory bowel disease (IBD) exhibits heterogeneous mucosal inflammation and variable responses to biologics therapy. This study aimed to identify the immune cell subsets and molecular programs driving disease pathogenesis and to develop predictive biomarkers for therapeutic outcomes.

Methods

We integrated single-cell RNA sequencing, bulk transcriptomic deconvolution, GWAS-based Mendelian randomization, and gut microbiome profiling across multiple IBD cohorts. Immune-microbial interactions were systematically characterized and linked with clinical phenotypes and treatment response. Immunohistochemistry was performed on colonic tissues from 12 IBD patients and 10 healthy controls to validate CCL5 and CD8 + T cell expression. Flow cytometric analysis of peripher

SUBMITTER: Wu S 

PROVIDER: S-EPMC12771841 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature